ADMA - ADMA Biologics, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $0.20
|
Rev Est: $139.8M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$16.00
DETAILS
HIGH:
$18.00
LOW:
$14.00
MEDIAN:
$16.00
CONSENSUS:
$16.00
UPSIDE:
3.09%
Market Cap:
3.69B
Volume:
2,288,136
Avg Volume:
2,376,076
52 Week Range:
13.5-25.67
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.48
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
685
IPO Date:
2013-10-17
EPS (TTM):
0.85
P/E Ratio:
20.22
Revenue (TTM):
426.45M
Total Assets:
488.68M
Total Debt:
82.12M
Cash & Equiv:
103.15M
Rev Growth (5Y):
70.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
32.2%
Debt/Equity:
0.24
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $0.16 | $0.16 | 0.0% | $134.2M | $139.8M | -4.0% |
| 2025-08-06 | $0.15 | $0.14 | +7.1% | $122.0M | $130.3M | -6.4% |
| 2025-05-07 | $0.14 | $0.16 | -12.5% | $114.8M | $121.8M | -5.7% |
| 2025-03-03 | $0.14 | $0.15 | -6.7% | $117.5M | $108.7M | +8.2% |
| 2024-11-07 | $0.15 | $0.13 | +15.4% | $119.8M | $113.4M | +5.7% |
| 2024-08-08 | $0.13 | $0.08 | +62.5% | $107.2M | $86.4M | +24.0% |
| 2024-05-09 | $0.08 | $0.06 | +33.3% | $81.9M | $77.3M | +6.0% |
| 2024-02-28 | $0.04 | $-0.01 | +420.0% | $73.9M | $72.2M | +2.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 426.45M | 258.21M | 154.08M | 80.94M | 42.22M | 29.35M | 16.99M | 22.76M | 10.66M | 7.18M | 5.92M | 3.07M |
| Net Income | 197.67M | (28.24M) | (65.90M) | (71.65M) | (75.75M) | (48.28M) | (65.74M) | (43.76M) | (19.52M) | (17.97M) | (16.81M) | (15.53M) |
| EPS | 0.85 | -0.13 | -0.43 | -0.61 | -1.02 | -1.05 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 |
| Total Assets | 488.68M | 329.18M | 348.46M | 276.25M | 207.67M | 127.09M | 88.88M | 108.02M | 23.69M | 23.71M | 27.23M | 31.98M |
| Total Debt | 82.12M | 141.42M | 154.44M | 102.92M | 97.67M | 84.73M | 44.22M | 42.97M | 20.26M | 15.73M | 14.97M | 5.08M |
| Cash & Equivalents | 103.15M | 51.35M | 86.52M | 51.09M | 55.92M | 26.75M | 22.75M | 43.11M | 9.91M | 10.44M | 17.20M | 26.15M |
| Operating Cash Flow | 118.67M | 8.80M | (59.51M) | (112.37M) | (102.00M) | (76.19M) | (62.68M) | (37.27M) | (18.27M) | (15.42M) | (14.70M) | (10.89M) |
| Free Cash Flow | 110.10M | 3.82M | (73.42M) | (125.88M) | (114.73M) | (80.01M) | (64.77M) | (39.95M) | (18.34M) | (15.44M) | (17.03M) | (11.08M) |
| FCF per Share | 0.47 | 0.02 | -0.37 | -0.90 | -1.33 | -1.47 | -1.43 | -1.74 | -1.51 | -1.48 | -1.83 | -1.70 |
| Book Value | 349.02M | 135.21M | 151.97M | 141.17M | 88.25M | 26.19M | 19.77M | 40.33M | (4.46M) | 820,974 | 6.01M | 21.57M |
| Cash & ST Investments | 103.15M | 51.35M | 86.52M | 51.09M | 55.92M | 26.75M | 22.75M | 43.11M | 15.31M | 16.81M | 21.85M | 29.08M |
| ROC Equity | 0.57 | -0.21 | -0.43 | -0.51 | -0.86 | -1.84 | -3.33 | -1.08 | N/A | -21.89 | -2.80 | -0.72 |